| abstract |
The use of a therapeutically effective amount of a non-immunosuppressive compound in the preparation of a medicament for treating neurological disorders in an animal, wherein the compound has affinity for FKBP-type immunophilins. FKBP-type immunophilin is FKBP-12. The immunophilin exhibits rotamase activity and the non-immunosuppressive compound inhibits the rotamase activity of immunophilin. The neurological disorder is selected from the group consisting of peripheral neuropathies and neurological pathologies associated with neurodegeneration. The neurological disorder may be Alzheimer's disease, Parkinson's disease, or amyotropic lateral sclerosis. The use of a therapeutically effective amount of a non-immunosuppressive compound in the preparation of a medicament for stimulating neuronal regeneration and growth in mammals, wherein the compound has affinity for FKBP-type immunophilins. FKBP-type immunophilin is FKBP-12. Immunophilin exhibits rotamase activity and a non-immunosuppressive neurotrophic compound inhibits the rotamase activity of immunophilin. Use of a therapeutically effective amount of a non-immunosuppressive compound in the preparation of a medicament for preventing neurodegeneration in an animal, wherein the compound has affinity for FKBP-type immunophilins. FKBP-type immunophilin is FKBP-12. Immunophilin exhibits rotamase activity and a non-immunosuppressive neurotrophic compound inhibits the rotamase activity of immunophilin. Use of a therapeutically effective amount of a non-immunosuppressive compound to stimulate the growth of damaged peripheral nerves |